Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Anti-lipolysis-stimulated lipoprotein receptor monoclonal antibody as a novel therapeutic agent for endometrial cancer

Fig. 1

Survival analysis of patients with endometrial cancer using immunohistochemistry for lipolysis-stimulated lipoprotein receptor (LSR). A Representative immunohistochemical finding of low-LSR expression; score 1 (weakly stained throughout the lesion). Scale bar, 200 μm. B Representative immunohistochemical finding of high-LSR expression; score 4 (strongly stained in > 50% of the lesion). Scale bar, 200 μm. C LSR was also highly expressed in lesions with myometrial invasion. Scale bar, 200 μm. D In omental metastatic lesions, high expression of LSR was observed. Scale bar, 200 μm. E In overall cohort (all histological subtypes), the 5-year overall survival rate in the high-LSR expression group (n = 153) was significantly lower compared with that in the low-LSR expression group (n = 75) (hazard ratio [HR]: 3.53, 95% confidence interval [CI]: 1.35–9.24, p = 0.01). F In high-grade carcinoma (grade 3 endometrioid and serous carcinoma), patients in the high-LSR expression group (n = 69) had a significantly poorer overall survival than those in the low-LSR expression group (n = 29) (HR: 3.02, 95% CI: 1.01–9.04, p = 0.048)

Back to article page